Navigation Links
Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference
Date:11/2/2007

potent inhibitor of the ADAM-10 and MMP-2 metalloprotease enzymes, targets of significant interest because of their important role in renal fibrosis and impairment. XL784 was specifically optimized to be matrix metalloprotease-1 (MMP-1) sparing, thus potentially significantly enhancing its safety profile and enabling higher dosing compared with other previously studied metalloprotease inhibitors. Results of single and repeat dose phase 1 clinical trials of XL784 administered orally to 70 healthy volunteers demonstrated that XL784 has attractive safety and pharmacokinetic profiles.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential safety and efficacy of XL784. Words such as "may," "expect," "suggest," "potentially" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events co
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 Touro College has announced ... CanniCare,s application for one of five media marijuana licenses to ... Dept. of Health (DOH).  If CanniCare ... medicinal cannabis.  "Our college is supportive of ... president of the Touro College System. "There is still a ...
(Date:7/29/2015)... 29, 2015  Cepheid (Nasdaq: CPHD ) ... to Xpert® Carba-R, with the addition of two ... on-demand, molecular test also detects and differentiates among ... namely KPC, NDM, VIM, IMP-1 and OXA-48. ... or Superbugs, are a growing and expensive challenge ...
(Date:7/29/2015)... July 29, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... developing innovative therapeutics primarily in the areas of dermatology ... results for the second quarter ended June 30, 2015 ... the U.S. financial markets.  A live ... webcast link is available under the "Investors" section of ...
Breaking Medicine Technology:Touro College Announces Support for CanniCare's Medical Cannabis License Application 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4RXi Pharmaceuticals to Webcast Second Quarter 2015 Financial Results on Wednesday, August 12, 2015 2RXi Pharmaceuticals to Webcast Second Quarter 2015 Financial Results on Wednesday, August 12, 2015 3
(Date:7/29/2015)... Madison, Wis. (PRWEB) , ... July 29, 2015 ... ... enrolled its first two patients in a Clinical Performance Study for the Invisiport ... includes 4.4 and 6 French catheter options, offers a less invasive, patient-friendly alternative ...
(Date:7/29/2015)... , ... July 29, 2015 , ... TransFlip is an ... as drag & drop presets for FCPX, these transitions are easy to apply and ... versatility to each transition. With over 60 preset styles, kinetic flipping panel animations are ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... decision from the Judicial Panel on Multidistrict Litigation (JPML), according to court documents.* ... research at their website, the Zofran Birth Defects Lawsuit Center. , GlaxoSmithKline, the ...
(Date:7/29/2015)... Scottsdale, Arizona (PRWEB) , ... July 29, 2015 , ... ... residential dorms. The project, which will by the end will cost the 501(c) organization ... compliance of Arizona’s recent anti-ligature requirements. , “We took it down to the ...
(Date:7/29/2015)... ... ... The Woodlands and Spring Fit Body Boot Camps have implemented an engaging an interactive ... new system will track each time a client uses social media to Check In ... camps will donate 20 cents to a selected charity. , Fit Body Boot Camp ...
Breaking Medicine News(10 mins):Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 2Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 3Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3
... , Sebelius Releases New Nationwide Emergency Department ... , ROCKVILLE, Md., July 15 Health and Human ... Emergency Department Sample -- the largest, all-payer emergency department database in ... to help public health experts, policymakers, health care administrators, researchers, journalists ...
... , SACRAMENTO, Calif., July 15 For the ... drop was 9.1 percent, from 1,132 in 2007 to 1,029 in 2008, ... The 2008 figure marks a total decrease of nearly 21 percent ... , Alcohol impaired deaths make up the largest category of ...
... , , Measure ... , , SILVER SPRING, Md., July 15 ... Choices Act," introduced yesterday in the House of Representatives. In particular, ... care option as a key component in reforming our broken health care ...
... , PRINCETON, N.J., July 15 Diabetes ... use the insulin in their pump for up to six ... of a labeling change, diabetes care company Novo Nordisk announced ... in the pump reservoir for two days. This makes NovoLog((R)) ...
... could improve cognition, vaccine might fight ,tangles, of disease ... show promise against two different types of brain abnormalities, ... progression of Alzheimer,s disease. , A drug called Dimebon ... humans but, new research reveals, it actually increases ...
... SHENZHEN, China, July 15 /PRNewswire-FirstCall/ - Hard to Treat ... company is now preparing for the tender business of ... specifications and details can be viewed by visiting this ... the second completed batch exported to Indonesia this year ...
Cached Medicine News:Health News:New Data Say Uninsured Account for Nearly One-Fifth of Emergency Room Visits 2Health News:New Data Say Uninsured Account for Nearly One-Fifth of Emergency Room Visits 3Health News:DUI Deaths Down 9 Percent in California 2Health News:United American Nurses Hails House Health Care Reform Bill 2Health News:FDA Approves NovoLog(R) Labeling Update 2Health News:FDA Approves NovoLog(R) Labeling Update 3Health News:FDA Approves NovoLog(R) Labeling Update 4Health News:New Treatments for Alzheimer's on the Horizon 2Health News:New Treatments for Alzheimer's on the Horizon 3Health News:Hard To Treat Diseases (HTDS.PK) Tender Order To Indonesia 2
Inquire...
... Aerosol barrier tips eliminate false ... Scientifically designed and tested, Promega Barrier ... working with amplified nucleic acids (PCR(a)), ... samples, forensic and serological specimens. , ...
... ideal for PCR and other ... work where aerosol contamination might ... pipetting DNA/RNA solutions, infectious materials, ... applications requiring absolute sterility, they ...
... eliminate false signals and contamination caused ... Promega Barrier Tips offer performance and ... acids (PCR(a)), radioactive isotopes, tissue culture ... specimens. , ,Promega Barrier Tips are ...
Medicine Products: